Meiji Yasuda Asset Management Co Ltd. Buys 7,430 Shares of Solventum Corporation $SOLV

Meiji Yasuda Asset Management Co Ltd. increased its stake in Solventum Corporation (NYSE:SOLV) by 29.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 32,482 shares of the company’s stock after purchasing an additional 7,430 shares during the quarter. Meiji Yasuda Asset Management Co Ltd.’s holdings in Solventum were worth $2,574,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of the stock. Vanguard Group Inc. raised its holdings in shares of Solventum by 5.3% in the 3rd quarter. Vanguard Group Inc. now owns 17,121,198 shares of the company’s stock worth $1,249,847,000 after purchasing an additional 867,837 shares during the period. Independent Franchise Partners LLP raised its holdings in shares of Solventum by 27.2% in the 3rd quarter. Independent Franchise Partners LLP now owns 12,899,240 shares of the company’s stock worth $941,645,000 after purchasing an additional 2,758,174 shares during the period. State Street Corp raised its holdings in shares of Solventum by 1.8% in the 3rd quarter. State Street Corp now owns 6,220,271 shares of the company’s stock worth $454,080,000 after purchasing an additional 112,261 shares during the period. Davis Selected Advisers raised its holdings in shares of Solventum by 12.7% in the 4th quarter. Davis Selected Advisers now owns 6,220,072 shares of the company’s stock worth $492,880,000 after purchasing an additional 702,461 shares during the period. Finally, Boston Partners raised its holdings in shares of Solventum by 26.1% in the 3rd quarter. Boston Partners now owns 4,630,300 shares of the company’s stock worth $338,006,000 after purchasing an additional 959,543 shares during the period.

Insider Activity at Solventum

In other news, Director Amy Mcbride Wendell purchased 1,475 shares of Solventum stock in a transaction dated Tuesday, March 10th. The stock was purchased at an average cost of $68.03 per share, for a total transaction of $100,344.25. Following the transaction, the director directly owned 5,039 shares of the company’s stock, valued at approximately $342,803.17. This trade represents a 41.39% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.24% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

SOLV has been the subject of a number of recent research reports. Wall Street Zen lowered shares of Solventum from a “buy” rating to a “hold” rating in a research note on Sunday, March 8th. Rothschild & Co Redburn initiated coverage on shares of Solventum in a research note on Tuesday, March 24th. They issued a “sell” rating and a $60.00 price objective for the company. KeyCorp lifted their price objective on shares of Solventum from $92.00 to $93.00 and gave the company an “overweight” rating in a research note on Wednesday, May 6th. Piper Sandler reduced their price objective on shares of Solventum from $98.00 to $92.00 and set an “overweight” rating for the company in a research note on Friday, April 17th. Finally, UBS Group lowered shares of Solventum from a “buy” rating to a “neutral” rating and set a $50.00 price objective for the company. in a research note on Thursday, May 14th. Eight research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $84.25.

Solventum Stock Up 0.2%

SOLV opened at $76.92 on Friday. The company has a fifty day moving average price of $68.68 and a 200-day moving average price of $74.77. The firm has a market capitalization of $13.32 billion, a P/E ratio of 9.43, a price-to-earnings-growth ratio of 1.19 and a beta of 0.59. The company has a debt-to-equity ratio of 0.96, a current ratio of 1.07 and a quick ratio of 0.75. Solventum Corporation has a one year low of $62.38 and a one year high of $88.20.

Solventum (NYSE:SOLV) last released its quarterly earnings results on Tuesday, May 5th. The company reported $1.48 EPS for the quarter, beating analysts’ consensus estimates of $1.35 by $0.13. The firm had revenue of $2.01 billion during the quarter, compared to analyst estimates of $1.97 billion. Solventum had a net margin of 17.33% and a return on equity of 23.51%. The business’s revenue for the quarter was down 3.0% on a year-over-year basis. During the same period in the previous year, the business earned $1.34 EPS. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. Equities research analysts expect that Solventum Corporation will post 6.57 earnings per share for the current fiscal year.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.